Sanofi files patent suit over Lantus biosimilar developed by MSD, Samsung Bioepis
Sept 21, 2016
French pharmaceutical giant Sanofi has filed a patent infringement lawsuit against US-based Merck & Co. over a Lantus biosimilar the US drugmaker developed with partial funding from Samsung Bioepis. Sanofi on Monday sued Merck & Co. in the US District Court of Delaware, claiming that Merck’s international division Merck Sharp & Dohme infringed as many as 10 patents held by the French drugmaker for its blockbuster diabetes treatment Lantus and its injection device SoloStar. The French company sai